Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2).
Alan S Maisel, Salvatore Di Somma
https://pubmed.ncbi.nlm.nih.gov/28028009/Actively Recruiting
Led by Martin Schweiger · Updated on 2025-11-17
225
Participants Needed
1
Research Sites
56 weeks
Total Duration
This research focuses on children under 18 years old scheduled for congenital heart surgery. It aims to evaluate the usefulness of a new blood biomarker called soluble suppression of tumorigenicity 2 sST2 in predicting heart failure. The study compares sST2 to other established biomarkers, seeking to improve risk assessment and management for pediatric patients with congenital heart disease, a common birth defect that can lead to serious heart complications after surgery. Participants are children planned for congenital cardiac surgery. Blood samples for sST2 and other biomarkers will be collected during surgery, post-operatively, and again at a follow-up visit 9 to 12 months later. The study observes the levels of sST2 independently and alongside other markers to assess its reliability, as sST2 may be less affected by factors like age or acute kidney injury. Throughout the study, patients will be monitored for signs of heart failure through clinical data, cardiac imaging, and hospital records within the first year after surgery. Researchers will track outcomes such as mortality, length of hospital stay, time on ventilation, ICU stay, and unplanned readmissions. The main measurement is the presence of heart failure signs one year after surgery, helping to better predict long-term risks for these children.
CONDITIONS
Blood Based Assessment of sST2, Taken During and After Surgery, for Pediatric Patients With Heart Defects to Predict Heart Failure.
M
Martin Schweiger, Prof, MD, MBA
C
Clemens Haselmann, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Martin Schweiger
Lead Sponsor
University Children's Hospital, Zurich
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Hospital stay around surgery (up to 30 days)
Participants undergo congenital cardiac surgery with biomarker assessments during and immediately after surgery to evaluate sST2 levels.
Visits during hospitalization including surgery day and immediate post-operative period
Duration - 30 days after surgery
Participants are monitored after surgery to assess heart function and signs of heart failure using clinical and biomarker evaluations.
Follow-up visits up to 30 days post-surgery
Duration - Up to 1 year post surgery
Participants are followed for up to one year after surgery to evaluate surrogates of heart failure and long-term outcomes.
Periodic visits during the first year after surgery
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Alan S Maisel, Salvatore Di Somma
https://pubmed.ncbi.nlm.nih.gov/28028009/Alberto Aimo, James L Januzzi, Antoni Bayes-Genis...
https://pubmed.ncbi.nlm.nih.gov/31648713/Jeremiah R Brown, Meagan E Stabler, Devin M Parker...
https://pubmed.ncbi.nlm.nih.gov/31290383/Magdalena Dudek, Marta Kałużna-Oleksy, Jacek Migaj...
https://pubmed.ncbi.nlm.nih.gov/37176577/Devin M Parker, Allen D Everett, Meagan E Stabler...
https://pubmed.ncbi.nlm.nih.gov/32246937/Martin Schweiger
Lead Sponsor
University Children's Hospital, Zurich
Collaborating Sponsor